Innovative funding partner throughout the growth life-cycle

Latest developments

News, Portfolio 06/04/2022              

PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility

 PolyPid Ltd. , a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company has entered into a secured loan agreement for up to $15 million with…
News, Portfolio 04/04/2022              

VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts

VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that it has entered two agreements that will strengthen the…
News, Portfolio 09/02/2022              

Quali’s magical journey from rejection to adoption

"It was magical. You feel like you're doing something that will alter for the better how large corporations work," said Edan Evantal, Quali CTO and one of its first employees,…

Subscribe to our mailing list

Get our newsletter, Kreos updates and information on our events right to your mailbox.

Market Leading Growth Debt Investor for +22 years

Kreos Capital provides innovative and flexible debt solutions to equity-backed, pan-European and Israeli high-growth companies in the technology and healthcare sectors.

For over 22 years, our sole focus has been to support our ambitious ecosystem with personal, adaptable and responsive financing through every stage of the growth life cycle – from entry level through to late-stage growth including pre and post-IPO.